# US 10,765,722 B2 · Angiotensin II alone or in combination for the treatment of hypotension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,722 B2
- Document ID: US10765722B2
- Status: Granted
- Kind: B2
- Application number: 16/135,608
- Filed: 2018-09-19
- Published: 2019-03-07
- Granted: 2020-09-08
- Earliest claimed: 2013-12-18
- Assignees: The George Washington University a Congressionally Chartered Not-for-Profit Corporation
- Applicants: The George Washington University a Congressionally Chartered Not-for-Profit Corporation
- Inventors: Lakhmir S. Chawla
- Web page: https://patentgrep.com/patent/US10765722B2

## CPC

- A61K 38/085: {Angiotensins}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.

## Claims

### Claim 1

A method of treating a hypotensive human patient suffering from acute kidney injury, comprising administering angiotensin II to the patient at an initial rate of about 0.25 to 10 ng/kg/min and titrating the rate down to achieve and/or maintain a target mean arterial pressure (MAP) of at least about 65 mmHg in the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the rate is titrated down to about 1.25-5 ng/kg/min.

### Claim 3 (depends on 1)

The method of claim 1, wherein the rate is titrated down to about 0.25-1.25 ng/kg/min.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient has sepsis, hepatorenal syndrome, or intra-glomerular hypotension.

### Claim 5 (depends on 1)

The method of claim 1, wherein the angiotensin II consists of SEQ ID NO: 1.

### Claim 6

A method of achieving a target mean arterial pressure (MAP) of at least about 65 mmHg in a hypotensive human patient experiencing acute kidney injury, comprising administering angiotensin II to the patient at an initial rate of about 0.25 to 10 ng/kg/min and titrating the rate down.

### Claim 7 (depends on 6)

The method of claim 6, wherein the dose is titrated down to about 1.25-5 ng/kg/min.

### Claim 8 (depends on 6)

The method of claim 6, wherein the dose is titrated down to about 0.25-1.25 ng/kg/min.

### Claim 9 (depends on 6)

The method of claim 6, wherein the patient has sepsis, hepato-renal syndrome, or intra-glomerular hypotension.

### Claim 10 (depends on 6)

The method of claim 6, wherein the angiotensin II consists of SEQ ID NO: 1.